Le Rhun E, et al. - Researchers analyzed pooled data from three randomized clinical trials in newly diagnosed glioblastoma including 1,273 patients to test the premise that, despite bleeding risk, anticoagulants improve the outcome in glioblastoma due to a lower incidence of venous thromboembolic events and modulation of angiogenesis, infiltration and invasion. They assessed survival associations of anticoagulant use from baseline up to the start of temozolomide chemoradiotherapy (TMZ/RT) (period I) and then to the start of maintenance TMZ chemotherapy (period II). With the use of anticoagulant, no improved overall survival (OS) was reported, instead, multivariate analysis revealed anticoagulant use during period II, but not period I, was related to inferior OS vs no use. For anti-platelet agent use, no survival association was established.